UBS Group
SPRY icon

UBS Group’s ARS Pharmaceuticals SPRY Stock Holding History

UBS Group’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.2M Buy
2,260,325
+49,459
+2% +$474K ﹤0.01% 2699
2025
Q4 		$25.8M Buy
2,210,866
+1,550,980
+235% +$15.1M ﹤0.01% 2337
2025
Q3 		$6.63M Sell
659,886
-207,049
-24% -$2.97M ﹤0.01% 3741
2025
Q2 		$15.1M Buy
866,935
+275,753
+47% +$3.98M ﹤0.01% 2672
2025
Q1 		$7.44M Sell
591,182
-421,519
-42% -$5.07M ﹤0.01% 3369
2024
Q4 		$10.7M Buy
1,012,701
+902,819
+822% +$12.6M ﹤0.01% 2962
2024
Q3 		$1.59M Buy
109,882
+44,960
+69% +$535K ﹤0.01% 4223
2024
Q2 		$552K Sell
64,922
-39,519
-38% -$351K ﹤0.01% 4927
2024
Q1 		$1.07M Buy
104,441
+102,713
+5,944% +$766K ﹤0.01% 4547
2023
Q4 		$9.47K Buy
+1,728
New +$7.57K ﹤0.01% 7488
2023
Q2 		– Sell
-2,903
Closed -$18.9K – 9594
2023
Q1 		$18.9K Buy
+2,903
New +$22.3K ﹤0.01% 7125
2022
Q4 		– Sell
-12
Closed – – 11121
2022
Q3 		$0 Sell
12
-490
-98% -$2.42K ﹤0.01% 10882
2022
Q2 		$2K Sell
502
-11
-2% -$38 ﹤0.01% 9613
2022
Q1 		$2K Sell
513
-78,327
-99% -$341K ﹤0.01% 9669
2021
Q4 		$525K Buy
78,840
+65,110
+474% +$529K ﹤0.01% 4938
2021
Q3 		$137K Buy
13,730
+13,555
+7,746% +$334K ﹤0.01% 5605
2021
Q2 		$5K Sell
175
-3,364
-95% -$108K ﹤0.01% 8568
2021
Q1 		$154K Buy
3,539
+3,446
+3,705% +$163K ﹤0.01% 5645
2020
Q4 		$4K Buy
+93
New +$3.11K ﹤0.01% 7931

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

UBS Group's SPRY Position: Q1 2026 in Review

UBS Group increased its ARS Pharmaceuticals (SPRY) stake by 2.2% in Q1 2026, buying an estimated $474K and bringing the position to 2,260,325 shares worth $18.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2699.

UBS Group first reported a position in SPRY in Q4 2020 and has held it in 19 quarters since. The position peaked at $25.8M in Q4 2025. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • UBS Group held 2,260,325 shares of ARS Pharmaceuticals worth $18.2M as of Q1 2026.
  • UBS Group bought 49,459 ARS Pharmaceuticals shares in Q1 2026, an estimated $474K.
  • ARS Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #2699 holding.
  • UBS Group first reported a position in ARS Pharmaceuticals in Q4 2020 and has held it in 19 quarters since.
  • UBS Group's ARS Pharmaceuticals position peaked at $25.8M in Q4 2025.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.